Chronic Lymphocytic Leukemia Clinical Trials

A listing of 77 Chronic Lymphocytic Leukemia clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Chronic Lymphocytic Leukemia

73 - 77 of 77

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 77 active clinical trials seeking participants for Chronic Lymphocytic Leukemia research studies. The states with the highest number of trials for Chronic Lymphocytic Leukemia participants are California, Ohio, Illinois and Michigan.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Clinical Study

Recruiting

We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.

Conditions:

Cough

Chronic Cough

Asthma

Allergic Asthma

Sinusitis

Learn More

Featured Trial

Healthy Volunteer Trials

Recruiting

Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!

Conditions:

Healthy

Learn More

Featured Trial

Healthy Volunteer Clinical Studies

Recruiting

Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.

Conditions:

Healthy

Healthy Volunteers

Learn More

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

NCT05718869

Recruiting

This phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein that signals cancer cells to multiply. This may stop the growth and spread of cancer cells. Givin... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

10/23/2023

Locations: City of Hope Medical Center, Duarte, California

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Learn More ›

Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia

NCT05677919

Recruiting

This phase II trial studies how well pirtobrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study also seeks to adopt a blood test which shows a small number of cancer cells in the body after cancer treatment called minimal residual disease as a guide to determine length of treatment. Drugs used in chemotherapy, such as pirtobrutinib and venetoclax, work in different ways to stop the growth of tumor cells, either by killing th... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

10/18/2023

Locations: Mayo Clinic in Rochester, Rochester, Minnesota

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Learn More ›

A Study Of The Selective PKC-β Inhibitor MS- 553

NCT03492125

Recruiting

A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Gender:

All

Ages:

18 years and above

Trial Updated:

03/13/2023

Locations: University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan +4 locations

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma

Learn More ›

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

NCT04502394

Recruiting

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

Gender:

All

Ages:

18 years and above

Trial Updated:

08/03/2022

Locations: Goshen Center for Cancer Care, Goshen, Indiana +44 locations

Goshen Center for Cancer Care, Goshen, Indiana

University of Cincinnati, Cincinnati, Ohio

The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

UT Southwestern Medical Center, Dallas, Texas

Royal Adelaide Hospital, Adelaide, Not set

Eastern Health - Box Hill Hospital, Box Hill, Not set

Barwon Health, Geelong, Not set

Royal Perth Hospital, Perth, Not set

Antwerp University Hospital (UZA), Edegem, Not set

Jessa Ziekenhuis, Hasselt, Not set

University Hospital (UZ) Leuven, Leuven, Not set

Fakultni Nemocnice Hradec Kralove, Nový Hradec Králové, Not set

Fakultni nemocnice Ostrava, Ostrava, Not set

Vseobecna fakultni nemocnice v Praze, Prague, Not set

CHU de Nantes - Hôtel-Dieu, Nantes, Not set

Centre Henri Becquerel, Rouen, Not set

CHRU de Tours - Hôpital Bretonneau, Tours, Not set

Centro Riferimento Oncologico - Aviano, Aviano, Not set

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

IRCCS Ospedale San Raffaele, Milano, Not set

Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

Centro Ricerche Cliniche di Verona s.r.l., Verona, Not set

National Cancer Center, Goyang, Not set

Gachon University Gil Medical Center, Incheon, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Seoul St. Mary's Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii, Gdansk, Not set

Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii, Gdańsk, Not set

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach - Klinika Transplantacji Szpiku i Onkohematologii, Gliwice, Not set

Szpital Uniwersytecki Krakow - Oddzial Kliniczny Hematologii, Krakow, Not set

Pratia MCM Krakow, Kraków, Not set

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw, Not set

Hospital de Braga, Braga, Not set

Centro Hospitalar Universitario de Lisboa Norte - Hospital de Santa Maria, Lisboa, Not set

Champalimaud Cancer Center, Lisbon, Not set

Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto, Not set

Centro Hospitalar de Vila Nova de Gaia/Espinho EPE, Vila Nova de Gaia, Not set

Kantonsspital St. Gallen, Saint Gallen, Not set

St James's University Hospital, Leeds, Not set

King's College Hospital, London, Not set

Royal Marsden Foundation Trust, London, Not set

University Hospital Southampton NHS Foundation Trust, Southampton, Not set

Conditions: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

Learn More ›

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT05211856

Recruiting

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.

Gender:

All

Ages:

Between 18 years and 130 years

Trial Updated:

01/14/2022

Locations: Research Site, Fountain Valley, California +277 locations

Research Site, Fountain Valley, California

Research Site, Fullerton, California

Research Site, La Jolla, California

Research Site, Los Angeles, California

Research Site, Redondo Beach, California

Research Site, Santa Barbara, California

Research Site, Hartford, Connecticut

Research Site, Orlando, Florida

Research Site, Chicago, Illinois

Research Site, Fort Wayne, Indiana

Research Site, Wichita, Kansas

Research Site, Louisville, Kentucky

Research Site, New Orleans, Louisiana

Research Site, Scarborough, Maine

Research Site, Baltimore, Maryland

Research Site, Boston, Massachusetts

Research Site, Worcester, Massachusetts

Research Site, Brick, New Jersey

Research Site, Florham Park, New Jersey

Research Site, New York, New York

Research Site, Charlotte, North Carolina

Research Site, Canton, Ohio

Research Site, Pittsburgh, Pennsylvania

Research Site, Fort Sam Houston, Texas

Research Site, Seattle, Washington

Research Site, Spokane, Washington

Research Site, Tacoma, Washington

Research Site, Madison, Wisconsin

Research Site, Buenos Aires, Not set

Research Site, Capital Federal, Not set

Research Site, Ciudad Autonoma Buenos Aires, Not set

Research Site, Córdoba, Not set

Research Site, Rosario, Not set

Research Site, Adelaide, Not set

Research Site, Darlinghurst, Not set

Research Site, Heidelberg, Not set

Research Site, Kogarah, Not set

Research Site, Melbourne, Not set

Research Site, Nedlands, Not set

Research Site, Perth, Not set

Research Site, South Brisbane, Not set

Research Site, Waratah, Not set

Research Site, Woolloongabba, Not set

Research Site, Graz, Not set

Research Site, Krems, Not set

Research Site, Linz, Not set

Research Site, Salzburg, Not set

Research Site, Vienna, Not set

Research Site, Antwerpen, Not set

Research Site, Kortrijk, Not set

Research Site, Yvoir, Not set

Research Site, Curitiba, Not set

Research Site, Goiania, Not set

Research Site, Porto Alegre, Not set

Research Site, Rio de Janeiro, Not set

Research Site, Sao Paulo, Not set

Research Site, São José do Rio Preto, Not set

Research Site, São Paulo, Not set

Research Site, Pleven, Not set

Research Site, Plovdiv, Not set

Research Site, Sofia, Not set

Research Site, Vratsa, Not set

Research Site, Calgary, Alberta

Research Site, Edmonton, Alberta

Research Site, Vancouver, British Columbia

Research Site, Ottawa, Ontario

Research Site, Toronto, Ontario

Research Site, Montreal, Quebec

Research Site, Quebec, Not set

Research Site, Beijing, Not set

Research Site, Changchun, Not set

Research Site, Changsha, Not set

Research Site, Chengdu, Not set

Research Site, Chongqing, Not set

Research Site, Dalian, Not set

Research Site, Fuzhou, Not set

Research Site, Guangzhou, Not set

Research Site, Haikou, Not set

Research Site, Hangzhou, Not set

Research Site, Jinan, Not set

Research Site, Lanzhou, Not set

Research Site, Nanchang, Not set

Research Site, Nanjing, Not set

Research Site, Shanghai, Not set

Research Site, Shenyang, Not set

Research Site, Shenzhen, Not set

Research Site, Tianjin, Not set

Research Site, Urumchi, Not set

Research Site, Wenzhou, Not set

Research Site, Wuhan, Not set

Research Site, Xian, Not set

Research Site, Zhengzhou, Not set

Research Site, Brno, Not set

Research Site, Hradec Kralove, Not set

Research Site, Olomouc, Not set

Research Site, Ostrava, Not set

Research Site, Plzen, Not set

Research Site, Praha 1, Not set

Research Site, Praha, Not set

Research Site, Aarhus, Not set

Research Site, Herlev, Not set

Research Site, København Ø, Not set

Research Site, Odense C, Not set

Research Site, Roskilde, Not set

Research Site, Marseille, Not set

Research Site, Montpellier Cedex 5, Not set

Research Site, Paris Cedex 10, Not set

Research Site, Paris, Not set

Research Site, Pessac, Not set

Research Site, Pierre Benite, Not set

Research Site, Rennes Cedex 9, Not set

Research Site, Rouen Cedex 1, Not set

Research Site, Toulouse Cedex 9, Not set

Research Site, Villejuif, Not set

Research Site, Erlangen, Not set

Research Site, Hamburg, Not set

Research Site, Kempten, Not set

Research Site, Köln, Not set

Research Site, Paderborn, Not set

Research Site, Potsdam, Not set

Research Site, Ulm, Not set

Research Site, Würzburg, Not set

Research Site, Budapest, Not set

Research Site, Debrecen, Not set

Research Site, Kaposvár, Not set

Research Site, Pécs, Not set

Research Site, Szeged, Not set

Research Site, Haifa, Not set

Research Site, Jerusalem, Not set

Research Site, Petah Tiqva, Not set

Research Site, Tel Aviv, Not set

Research Site, Tel Hashomer, Not set

Research Site, Brescia, Not set

Research Site, Cagliari, Not set

Research Site, Meldola, Not set

Research Site, Milano, Not set

Research Site, Novara, Not set

Research Site, Palermo, Not set

Research Site, Ravenna, Not set

Research Site, Roma, Not set

Research Site, Torino, Not set

Research Site, Incheon, Not set

Research Site, Seoul, Not set

Research Site, Ulsan, Not set

Research Site, D.F, Not set

Research Site, Mexico City, Not set

Research Site, Mexico, Not set

Research Site, Monterrey, Not set

Research Site, Morelia, Not set

Research Site, Alkmaar, Not set

Research Site, Almere, Not set

Research Site, Amsterdam, Not set

Research Site, Arnhem, Not set

Research Site, Breda, Not set

Research Site, Den Bosch, Not set

Research Site, Dordrecht, Not set

Research Site, Nieuwegein, Not set

Research Site, Rotterdam, Not set

Research Site, Utrecht, Not set

Research Site, Callao, Not set

Research Site, Lima, Not set

Research Site, Brzozów, Not set

Research Site, Bydgoszcz, Not set

Research Site, Gdańsk, Not set

Research Site, Gdynia, Not set

Research Site, Kraków, Not set

Research Site, Lublin, Not set

Research Site, Wrocław, Not set

Research Site, Łódź, Not set

Research Site, Moscow, Not set

Research Site, Nizhny Novgorod, Not set

Research Site, Novosibirsk, Not set

Research Site, Ryazan, Not set

Research Site, Saint Petersburg, Not set

Research Site, Saint-Petersburg, Not set

Research Site, Samara, Not set

Research Site, Sochi, Not set

Research Site, St Petersburg, Not set

Research Site, Tula, Not set

Research Site, Volgograd, Not set

Research Site, Dammam, Not set

Research Site, Jeddah, Not set

Research Site, Riyadh, Not set

Research Site, Bratislava, Not set

Research Site, Kosice, Not set

Research Site, Bloemfontein, Not set

Research Site, Cape Town, Not set

Research Site, Johannesburg, Not set

Research Site, Pretoria, Not set

Research Site, Randburg, Not set

Research Site, Badalona(Barcelona), Not set

Research Site, Barcelona, Not set

Research Site, Madrid, Not set

Research Site, Majadahonda, Not set

Research Site, Salamanca, Not set

Research Site, Santander, Not set

Research Site, Valencia, Not set

Research Site, Göteborg, Not set

Research Site, Uppsala, Not set

Research Site, Örebro, Not set

Research Site, Kaohsiung, Not set

Research Site, Taichung, Not set

Research Site, Tainan City, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan City, Not set

Research Site, Ankara, Not set

Research Site, Istanbul, Not set

Research Site, Izmir, Not set

Research Site, Kurupelit, Not set

Research Site, Talas, Not set

Research Site, Trabzon, Not set

Research Site, Cherkasy, Not set

Research Site, Dnipro, Not set

Research Site, Ivano-Frankivsk, Not set

Research Site, Kharkiv Region, Not set

Research Site, Khmelnytskyi, Not set

Research Site, Kyiv, Not set

Research Site, Zhytomyr, Not set

Research Site, Cambridge, Not set

Research Site, Canterbury, Not set

Research Site, Leeds, Not set

Research Site, Newcastle-Upon-Tyne, Not set

Research Site, Shrewsbury, Not set

Research Site, Wolverhampton, Not set

Conditions: Chronic Lymphocytic Leukemia

Learn More ›

73 - 77 of 77